Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07536269
PHASE2

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Crinecerfont in Participants With Classic Congenital Adrenal Hyperplasia (CAH) Who Are Less Than 4 Years Old

Sponsor: Neurocrine Switzerland GmbH

View on ClinicalTrials.gov

Summary

The main objective of this study is to assess the safety and tolerability of crinecerfont in pediatric participants 3 months to \<4 years of age with CAH.

Official title: A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia

Key Details

Gender

All

Age Range

3 Months - 47 Months

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2026-07-01

Completion Date

2028-03

Last Updated

2026-09-16

Healthy Volunteers

No

Interventions

DRUG

Crinecerfont

Oral solution

Locations (11)

Neurocrine Clinical Site

San Francisco, California, United States

Neurocrine Clinical Site

Aurora, Colorado, United States

Neurocrine Clinical Site

Hartford, Connecticut, United States

Neurocrine Clinical Site

Atlanta, Georgia, United States

Neurocrine Clinical Site

Chicago, Illinois, United States

Neurocrine Clinical Site

Indianapolis, Indiana, United States

Neurocrine Clinical Site

Ann Arbor, Michigan, United States

Neurocrine Clinical Site

Minneapolis, Minnesota, United States

Neurocrine Clinical Site

Philadelphia, Pennsylvania, United States

Neurocrine Clinical Site

Dallas, Texas, United States

Neurocrine Clinical Site

Seattle, Washington, United States